Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina



Status:Recruiting
Conditions:Angina, Angina
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:20 - 80
Updated:4/21/2016
Start Date:August 2012
End Date:December 2016
Contact:Martin Lucas
Email:Martin.Lucas@iconplc.com
Phone:+1 215 616 3540

Use our guide to learn which trials are right for you!

Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic® (T89) in Patients With Chronic Stable Angina

This phase III study is designed as a double blind, randomized, multi-nation, multi-center,
placebo controlled clinical research, which aims to evaluate the safety and efficacy of
Dantonic® (T89) in patients with chronic stable angina pectoris.

Dantonic® (T89) is a botanical drug consists of extracts of Danshen (Radix Salviae
Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. The drug is
currently approved in 26 countries outside the USA for the treatment and prevention of
chronic stable angina pectoris and other cardiovascular disease related conditions. This
pivotal confirmative Phase III clinical trial is to confirm the efficacy and safety of the
drug at 150mg and 225mg doses in the prevention and treatment of angina pectoris in patients
with Chronic Stable Angina. The contribution of the main herb Danshen to, and the difference
of various production batches in, the overall efficacy and safety profiles will also be
explored. Patients will take a morning and an evening dose orally (every 12 hours) for 6
weeks while stop taking any long-acting nitroglycerin, ranolazine, and/or multiple
beta-blockers or beta blocker(s) with calcium channel blocker during the trial. Single
beta-blocker and/or on-demand short acting nitroglycerin to relief angina pectoris is
allowed during the trial. After physical exams and if eligible to participation, patients
will stop taking other drugs, and undergo two baseline screen Exercise Treadmill Tests (ETT)
on Standard Bruce Protocol in the clinic one week before and right before starting the drug
treatment. Patients will perform three more ETTs before the morning dose at the end of week
2, 4 and 6 after receiving the drug treatment. The primary efficiency endpoint is the change
of symptom-limited Total Exercise Duration of the ETT at the end of the 4th week of
treatment from the average of the two screening baselines compared with that of placebo
treatment.

Inclusion Criteria:

1. Written informed consent.

2. Males and females between the ages of 20 and 80 years.

3. Females of childbearing potential must have a negative pregnancy test, not be breast
feeding and established on a method of contraception that in the investigator's
opinion is acceptable. Females must agree to remain on their established method of
contraception through their participation in the study and for 14 days following the
last dose of study drug.

4. Evidence of coronary artery disease that consists of a well-documented medical
history (over 3 months prior to the enrolment) of myocardial infarction or
significant coronary artery disease with noninvasive or angiographic confirmation.

5. Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal
exercise response limited by angina and/or electrocardiograph (ECG) changes.

6. Moderate angina pectoris (Class II or III, Grading of Angina Pectoris by the Canadian
Cardiovascular Society Classification System).

7. Patient whose symptom-limited Total Exercise Duration (TED) is between 3 to 7 minutes
in Exercise Tolerance Test (ETT) on Standard Bruce Protocol, and symptom-limited TED
on two screen examinations (Day -7 and 0) in which the shorter is within 85% of the
longer .

8. Patient has been on one beta-blocker or on one calcium-channel blocker for at least
14 days prior to dosing of study medication and can remain on this treatment
throughout the study as background anti-anginal treatment. Short-acting nitroglycerin
for on-demand use is allowed for all eligible patients.

9. Understand and be willing, able and likely to comply with all study procedures and
restrictions and comprehends the verbal rating scales and diary cards.

Exclusion Criteria:

1. With contraindication to, unable to, or with other co-morbidities that may prevent or
interfere with the ability to perform treadmill ETT (including, but not limited to:
pulmonary hypertension, functionally limiting COPD (chronic obstructive pulmonary
disease), history of pulmonary tuberculosis, prior hospitalization for acute
exacerbation of chronic lung disease, home oxygen use, chronic oral steroid therapy
that can limit exercise capacity, functionally limiting peripheral artery disease,
etc.).

2. Presence of electrocardiographic or other abnormalities/factors that could interfere
with exercise electrocardiograph interpretation or may lead to a false positive
stress test (e.g., pre-exercise horizontal or down-sloping ST segment depression in
any standard lead, cardiac glycoside therapy, Lown-Ganong-Levine Syndrome,
Wolff-Parkinson-White syndrome (WPW), left bundle branch block, left ventricular
hypertrophy with repolarization abnormality, implanted pacemaker, etc.).

3. Clinically significant arrhythmias or atrioventricular conduction block greater than
first degree, decompensated heart failure, atrial fibrillation, hypertrophic
cardiomyopathy.

4. Acute coronary syndrome (acute myocardial infarction or unstable angina) in the prior
2 months or coronary revascularization within the prior 6 months or planned coronary
revascularization during the study period.

5. Congenital cardiac defects, ongoing history of decompensated congestive heart
failure, severe valvular disease, severe uncontrolled hypertension (seated systolic
blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg), severe anemia,
suspected or known dissecting aortic aneurysm, acute myocarditis or pericarditis,
thrombophlebitis or pulmonary embolism.

6. History of bleeding diathesis, cerebral hemorrhage, or seizure disorders that
required anticonvulsant medication.

7. Patients requiring the use of long-acting nitroglycerin, ranolazine, and/or multiple
anti-anginal drugs.

8. Aspirin and/or statins started less than 14 days prior to the signing of informed
consent.

9. Pregnancy or lactation.

10. Clinical trials/experimental medication 1) Participation in any other clinical trial
or receipt of an investigational drug within 30 days prior to the initial visit.

2) Previous participation in the studies of T89. 11. Substance abuse. Patients with a
recent history (within the last 2 years) of alcoholism or known drug dependence.

12. Is a family member or relative of the study site staff. 13. Any other conditions that,
in the opinion of the investigator, are likely to prevent compliance with the study
protocol or pose a safety concern if the subject participates in the study.
We found this trial at
31
sites
Tullahoma, Tennessee 37388
Phone: 931-461-2663
?
mi
from
Tullahoma, TN
Click here to add this to my saved trials
4085 University Blvd S # 1
Jacksonville, Florida 32216
Phone: 904-730-0101
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
1000 W Carson St
Torrance, California 90502
Phone: 310-222-2415
?
mi
from
Torrance, CA
Click here to add this to my saved trials
Alexandria, Louisiana 71301
Phone: 318-473-4613
?
mi
from
Alexandria, LA
Click here to add this to my saved trials
Athens, Georgia 30606
Phone: 706-208-9700
?
mi
from
Athens, GA
Click here to add this to my saved trials
Atlanta, Georgia 30342
Phone: 404-600-6343
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30342
Phone: 404-796-7011
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Banning, California 92220
Phone: 951-845-0313
?
mi
from
Banning, CA
Click here to add this to my saved trials
Campbellsville, Kentucky 42718
Phone: 270-765-5921
?
mi
from
Campbellsville, KY
Click here to add this to my saved trials
Hillsboro, Oregon 97123
Phone: 503-648-0731
?
mi
from
Hillsboro, OR
Click here to add this to my saved trials
Houston, Texas 77025
Phone: 877-339-0254
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77070
Phone: 281-469-8007
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jackson, Tennessee 38305
Phone: 731-512-0104
?
mi
from
Jackson, TN
Click here to add this to my saved trials
Katy, Texas 77450
Phone: 832-321-3317
?
mi
from
Katy, TX
Click here to add this to my saved trials
La Jolla, California 92037
Phone: 858-625-4488
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Little Rock, Arkansas 72204
Phone: 501-664-0941
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Medina, Ohio 44256
Phone: 330-721-5700
?
mi
from
Medina, OH
Click here to add this to my saved trials
Merritt, Florida 32952
Phone: (321) 434-6650
?
mi
from
Merritt, FL
Click here to add this to my saved trials
Miami, Florida 33144
Phone: 786-343-6937
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33156
Phone: 305-972-0338
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami, Florida 33165
Phone: 305-220-3600
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami Beach, Florida 33140
Phone: 305-858-4300
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Minsk, 22304
Phone: +375(29)6062070
?
mi
from
Minsk,
Click here to add this to my saved trials
National City, California 91950
Phone: 619-453-3658
?
mi
from
National City, CA
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10016
Phone: 212-480-3333
?
mi
from
New York, NY
Click here to add this to my saved trials
Ormond Beach, Florida 32174
Phone: 386-677-0525
?
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Sarasota, Florida 34239
Phone: 941-366-9800
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Tampa, Florida 33604
Phone: 813-899-1394
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Tomball, Texas 77375
Phone: 281-351-6250
?
mi
from
Tomball, TX
Click here to add this to my saved trials
Torrance, California 90502
Phone: 310-370-4558
?
mi
from
Torrance, CA
Click here to add this to my saved trials